Literature DB >> 29545369

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

William Pao1, Chia-Huey Ooi2, Fabian Birzele2, Astrid Ruefli-Brasse2, Michael A Cannarile3, Bernhard Reis2, Sebastian H Scharf2, David A Schubert2, Klas Hatje2, Nadege Pelletier2, Olivia Spleiss2, John C Reed2.   

Abstract

Checkpoint inhibitor therapy has been a breakthrough in cancer research, but only some patients with cancer derive substantial benefit. Although mechanisms underlying sensitivity and resistance to checkpoint inhibitors are being elucidated, the importance of organ-specific regulation of immunity is currently underappreciated. Here, we call for a greater understanding of tissue-specific immunoregulation, namely, "tissue-specific immunostats," to make advances in treatments for cancer. A better understanding of how individual organs at baseline regulate the immune system could enable an improved precision medicine approach to cancer immunotherapy. Cancer Discov; 8(4); 395-402. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29545369     DOI: 10.1158/2159-8290.CD-17-1320

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  30 in total

1.  Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes.

Authors:  Eric Salgado; Yanguang Cao
Journal:  Math Biosci Eng       Date:  2020-11-19       Impact factor: 2.080

2.  Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing.

Authors:  Francesca Maria Bosisio; Asier Antoranz; Yannick van Herck; Maddalena Maria Bolognesi; Lukas Marcelis; Clizia Chinello; Jasper Wouters; Fulvio Magni; Leonidas Alexopoulos; Marguerite Stas; Veerle Boecxstaens; Oliver Bechter; Giorgio Cattoretti; Joost van den Oord
Journal:  Elife       Date:  2020-02-14       Impact factor: 8.140

3.  Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression.

Authors:  Minehiko Inomata; Naoki Takata; Isami Mizushima; Kenji Azechi; Kana Hayashi; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Shingo Imanishi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Kazuyuki Tobe
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 4.  Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Authors:  Joy J Bianchi; Xin Zhao; Joseph C Mays; Teresa Davoli
Journal:  Curr Opin Cell Biol       Date:  2020-02-21       Impact factor: 8.382

5.  Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

Authors:  Juan C Osorio; Kathryn C Arbour; Dung T Le; Jennifer N Durham; Andrew J Plodkowski; Darragh F Halpenny; Michelle S Ginsberg; Peter Sawan; Joseph G Crompton; Helena A Yu; Azadeh Namakydoust; Barzin Y Nabet; Jamie E Chaft; Gregory J Riely; Hira Rizvi; Luis A Diaz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2019-11-01       Impact factor: 44.544

6.  Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Authors:  Inna Smalley; Zhihua Chen; Manali Phadke; Jiannong Li; Xiaoqing Yu; Clayton Wyatt; Brittany Evernden; Jane L Messina; Amod Sarnaik; Vernon K Sondak; Chaomei Zhang; Vincent Law; Nam Tran; Arnold Etame; Robert J B Macaulay; Zeynep Eroglu; Peter A Forsyth; Paulo C Rodriguez; Y Ann Chen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2021-05-25       Impact factor: 12.531

Review 7.  Promises and challenges of adoptive T-cell therapies for solid tumours.

Authors:  Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D Brenton; Stuart M Curbishley; Tao Dong; Michael L Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L Miller; Laura Santana-Gonzalez; Leonard W Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N Church; David C Wedge; Ahmed A Ahmed
Journal:  Br J Cancer       Date:  2021-03-29       Impact factor: 7.640

Review 8.  Toward personalized treatment approaches for non-small-cell lung cancer.

Authors:  Meina Wang; Roy S Herbst; Chris Boshoff
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

9.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

Authors:  A J Schoenfeld; H Rizvi; C Bandlamudi; J L Sauter; W D Travis; N Rekhtman; A J Plodkowski; R Perez-Johnston; P Sawan; A Beras; J V Egger; M Ladanyi; K C Arbour; C M Rudin; G J Riely; B S Taylor; M T A Donoghue; M D Hellmann
Journal:  Ann Oncol       Date:  2020-02-06       Impact factor: 32.976

Review 10.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.